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Abstract
Background: Genomic alterations affecting drug target proteins occur in several
tumor types and are prime candidates for patient-specific tailored treatments.
Increasingly, patients likely to benefit from targeted cancer therapy are selected based
on molecular alterations. The selection of a precision therapy benefiting most patients
is challenging but can be enhanced with integration of multiple types of molecular
data. Data integration approaches for drug prioritization have successfully integrated
diverse molecular data but do not take full advantage of existing data and literature.
Results: We have built a knowledge-base which connects data from public databases
with molecular results from over 2200 tumors, signaling pathways and drug-target
databases. Moreover, we have developed a data mining algorithm to effectively utilize
this heterogeneous knowledge-base. Our algorithm is designed to facilitate retargeting
of existing drugs by stratifying samples and prioritizing drug targets. We analyzed 797
primary tumors from The Cancer Genome Atlas breast and ovarian cancer cohorts
using our framework. FGFR, CDK and HER2 inhibitors were prioritized in breast and
ovarian data sets. Estrogen receptor positive breast tumors showed potential sensitivity
to targeted inhibitors of FGFR due to activation of FGFR3.
Conclusions: Our results suggest that computational sample stratification selects
potentially sensitive samples for targeted therapies and can aid in precision medicine
drug repositioning. Source code is available from http://csblcanges.fimm.fi/GOPredict/.
Keywords: Data integration, Drug prioritization, Gene ontology, Cancer, Breast cancer
Background
Finding the right drug for the right patient is an integral part of precision medicine and
computational methods to facilitate matching patients to drugs are urgently needed [1].
Patient stratification using clinical or molecular features to identify patients that most
likely respond to a drug allows reducing costs in drug development [2], maximizing
the number of responding patients [3], and minimizing side-effects to non-responding
patients [4]. Patient-stratified analysis in a cancer may result in suggestions of drugs that
have not been indicated in cancer care earlier. This so called drug repositioning offers
novel opportunities to find effective treatments for cancer patients.
The molecular landscape of a tumor affects the efficacy of several drugs and is central
for clinical trial design for targeted therapies [5]. In particular, molecular level alterations,
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such as point mutations, somatic copy-number amplifications and promoter hypomethy-
lation, play key roles in both stratifying patients and finding drugs for repositioning [6].
For instance, genomic alterations affecting the production of drug target proteins occur
in several tumor histological types as exemplified by druggable HER2 mutations in both
breast and metastatic gastric cancer [3]. These drug target proteins, which are genomi-
cally altered in multiple cancers, are thus prime candidates for precision medicine drug
repositioning [7, 8]. In addition, utilization of signaling networks offers possibilities for
improving cancer drug treatments [9].
The large variety of molecular level alterations in cancers calls for computational data
integration methods to enable precision medicine via improved patient stratification and
drug repositioning [10–12]. Most integration methods use two or three types of molecu-
lar alterations and seldom incorporate in a single algorithm signaling pathway or curated
information available in databases [13, 14]. For instance, [15] used transcriptomics data in
drug prioritization whereas theMOCA algorithm integrated genomics data with Boolean
set operations to build multigene-modules to predict drug responses and stratify cell
lines in a pan-cancer setting [16]. In particular, knowledge available in open-access can-
cer genomic studies represents a large untapped resource for enhancing interpretation of
analysis results.
We introduce here a computational algorithm called GOPredict that allows patient
stratification and drug repositioning via comprehensive integration of genomics data, sig-
naling pathway information, drug target databases and curated knowledge in databases.
We demonstrate the utility of GOPredict by stratifying Cancer Genome Atlas (TCGA)
breast and ovarian cancer samples and prioritizing drugs in these two cohorts [17–19].
Methods
Our data integration approach consists of two major steps. First, we have developed
a knowledge-base that contains molecular, drug information and analysis results from
multiple public databases and private sources. Second, we have developed an algorithm
(GOPredict) to mine the knowledge-base. An overall schematic of the approach is given
in Fig. 1.
The major design principles of the knowledge-base are as follows. First, the knowledge-
base is gene-centric (meaning that the information in the knowledge-base is associated
to a gene identifier) because this allows taking into account published results that are
Fig. 1 Conceptual overview of GOPredict. In-house and curated data (left) are used to create a gene-by-study
matrix of ranks which is stored in the knowledge-base (large blue box). GOPredict uses the genewise study
ranks to calculate gene K-ranks (yellow box, left). K-ranks are used to calculate cancer-essentiality for GO
processes (yellow box,middle). K-ranks are recalibrated with GO process scores and then used to prioritize
drugs and stratify samples for input query data sets
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mostly gene-centric. This design also allows automated analysis of drug-gene target-pairs.
Second, results in the knowledge-base are stored as ranks. The use of ranks enables
comparing and combining data over multiple data sets, data types, and measurement
technologies as well as between numerical, ordinal and categorical data [20]. In addition,
rank-based scoring is less biased towards well-studied genes [21].
GOPredict uses signaling pathway information defined with Gene Ontology (GO) bio-
logical processes [22]. The Gene Ontology contains high level processes (e.g., ’apoptosis’)
as well as specific signaling pathways (e.g., ’ERBB signaling pathway’). Unlike other sig-
naling pathway databases [23], the GO and its standardized naming conventions for
biological processes provide a flexible and reliable data source to define signaling pathway
context for genes [24].
The underlying modeling question for GOPredict is “what is the best drug to target pro-
teins affected by genomic aberrations and driving tumorigenic signaling in tumors”. The
GOPredict algorithm is described in detail in Additional file 1. Briefly, gene-based rank
data from the knowledge-base is related to the GO processes that genes regulate. Each
gene-drug target pair is then prioritized based on the GO processes, that the gene regu-
lates, and the priority rank of a drug is averaged over all genes which the drug regulates. In
this section we use select examples to provide a general description of the knowledge-base
and GOPredict.
Data sets
We gathered results of genomic, transcriptomic, and epigenomic (DNAmethylation), and
descriptive (gene-phenotype connections) analysis data from nine public cancer data sets.
Each data set consisted of one or more of these data levels. There are two sources of data
which we call in-house data and curated data. In-house data comprise raw data that we
downloaded and analyzed. Curated data comprise analyzed gene-level result data that we
downloaded from the source databases and did not process further. A short description
of studies is in Table 1 and a more detailed list in Additional file 2.
The in-house data comprise four Cancer Genome Atlas (TCGA) primary tumor data
sets totaling approximately 2,200 samples of breast, ovarian, colorectal and glioblastoma
brain cancer [17–19, 25]. Three of the data sets, glioblastoma, breast and ovarian can-
cer, we had previously analyzed [26–28]. The curated data comprise Tumorscape [29],
COSMIC [30, 31], the Cancer Gene Census genes [30], the amplified and overexpressed
Table 1 List of in-house (TCGA) and curated data sets in the knowledge-base. A more detailed
description of each data set, data type and study is in Additional files 1 and 2
Data source Study type Number of studies
In-house (analysis based) Somatic CNA (gain frequency, deletion frequency, survival) 11
DNA methylation (survival) 4
Expression (survival, fold-change) 8
Curated (literature based) Amplified and overexpressed cancer genes 1
Breast cancer brain metastasis genes 1
Cancer Gene Census activated 1
Cancer Gene Census inactivated 1
COSMIC 3
Tumorscape 20
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genes in cancer collection [32], and a breast cancer brain metastasis gene collection [33]
(Additional file 1). The download and analysis of the in-house data are automated using
Anduril computational infrastructure [26]. Details of the in-house analysis of the TCGA
data are provided in Additional file 1.
Knowledge-base
The knowledge-base comprises analysis results from the in-house and curated data sets.
Conceptually, in-house and curated data are composed of one or more studies in the
knowledge-base. A study is a ranked list of genes that are ranked based on a statistical
analysis of a molecular data type in a specific cancer or literature source. All studies are
stored gene-wise and for each gene the database contains its rank order in each study
(Methods, Additional file 1). For each study only those genes, which meet study spe-
cific inclusion criteria, receive ranks and are connected to a study. For example, a gene
is ranked based on its fold-change in an in-house data expression analysis if the differ-
ence in means of gene expression values between tumor and control samples is significant
(t-test q ≤ 0.001, Benjamini-Yakutieli multiple hypothesis correction [34]). Full details of
all inclusion criteria are given in Additional file 1.
Studies can be combined into study sets. Users can tailor and modify study sets flex-
ibly to suit different research questions. We provide three default study sets: activating
(containing e.g., gene upregulation and gene copy-number increase results from the four
in-house TCGA data sets), inactivating (e.g., gene downregulation, gene copy-number
deletion), or survival-associated (univariate association of gene copy-number increase
with overall survival). A gene may belong to one or several studies and study sets. A full
list of studies in each default study set is in Additional file 1. The default study sets were
constructed conservatively only to contain studies which unambiguously fit into these
study set definitions.
In addition to gene ranks in studies, the knowledge-base contains drug gene-target
information from KEGGDrug [35] and DrugBank [36], and signaling pathways from the
Gene Ontology (http://geneontology.org/, downloaded August 2013). This compound
design enables rapid integration, combination and comparison of data over multiple data
sets, data types, andmeasurement technologies. KEGGDrug, DrugBank and Gene Ontol-
ogy are stored in the database as described in Additional file 1 and by [37]. DrugBank and
KEGGDrug contain approved drugs and experimental compounds. For notational con-
venience, we use the word ‘drug’ to refer to all compounds retrieved from DrugBank and
KEGGDrug.
Cancer-essentiality scoring and gene ranks
The overall goals of the GOPredict algorithm are to prioritize drugs with known pro-
tein targets, characterize genes, and stratify samples. GOPredict works in four steps
(Additional file 1: Figure S1). The first and second steps are preparatory. In the third step
samples are stratified and in the fourth drugs are prioritized.
First, gene ranks are extracted from the database for each study and used to calculate
normalized gene ranks called the K-ranks (Additional file 1: Figure S1a). For exam-
ple, the fibroblast growth factor receptor 3 (FGFR3) has a rank in two studies which
are used to calculate its K-rank. The two studies for FGFR3 are a curated study (acti-
vating mutations in the Cancer Gene Census) and an in-house study (differential gene
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expression in TCGA breast cancer). Each K-rank quantifies the cancer-essentiality of a
gene.
Second, since genes are connected to GO processes, the K-ranks are used to calcu-
late GOPredict cancer-essentiality scores for GO processes (Additional file 1: Figure S1b).
The higher the score, the more cancer-essential the GO process is. For example, 1130
genes negatively and 939 positively regulate ‘cell development’ (GO:0048468) and have
a K-rank in the database (see previous section and Additional file 1 for K-rank inclu-
sion criteria). The K-ranks of these genes from step one are summed up to produce the
cancer-essentiality score for ‘cell development’ and statistical significance is assessed with
a permutation test (Additional file 1).
Sample stratification and drug prioritization
Before explaining the third and fourth steps of GOPredict, we first need to clarify inputs
to GOPredict. The input to the third and fourth steps of GOPredict is called a query data
set (Fig. 1). A query data set consists of molecular data for a set of samples in which we
want to stratify samples for drug prioritization. The third and fourth steps of GOPredict
produce the drug prioritization and sample stratification for an input query data set.
To prioritize drugs, we first construct for each query data set an activity matrix using a
set of biologically motivated logical rules based on the molecular measurement data such
gene expression, gene copy-number and mutation data (Additional file 1). The activity
matrix is a gene-by-sample binarymatrix denoting the status (active, inactive, unchanged)
of a gene. The status of a gene is preferably defined by its expression status. In cases
where a gene’s expression status conflicts with its copy-number state and copy-number
is altered, copy-number takes precedence (full details in Additional file 1). The rationale
for prioritizing genomic alterations is that they are more stable and reproducible over
different studies than expression level alterations, and therefore are more viable as can-
didate biomarkers [38]. The activity matrix is also used when interpreting results of drug
prioritization because sample stratification is extracted from the activity matrix.
In step three, the GO processes’ cancer-essentiality score P-values are used to recali-
brate gene K-ranks. The recalibrated K-rank is the harmonic mean of P-values of all GO
processes a gene regulates (Additional file 1: Figure S1c). In ambiguous cases where a
gene is annotated both as a positive and negative regulator of a GO process, that GO pro-
cess is not used in the calculation. For example, FGFR3 unambiguously regulates 17 GO
processes, 9 positively and 8 negatively, of which two are depicted in Additional file 1:
Figure S1c. The recalibration 1) connects signaling pathways to drug target genes and 2)
normalizes the scores so that highly connected processes (terms that are high in the GO
hierarchy and therefore connected to more genes) do not dominate the results. Without
recalibration, drug scores would be biased towards more highly connected biological pro-
cesses. Only a subset of genes receive recalibrated ranks. Genes that code for drug target
proteins in the knowledge-base and are in the activity matrix (implying they are altered in
the query data set) are used for prioritization. Other genes are removed and the final set
of genes only contains genes that are drug targets.
In step four, recalibrated gene K-ranks are used to prioritize drugs (Additional file 1:
Figure S1d). The prioritization score balances (1) the number of targets of a drug; (2) the
relevance of the drug targets according to the database; and (3) the measured activity of
the target gene in input cancer data.
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Results
To demonstrate the use of the knowledge-base and GOPredict, we downloaded and
analyzed with GOPredict 497 primary breast carcinoma (BRCA) and 390 ovarian ade-
nocarcinoma (OVCA) tumors from the Cancer Genome Atlas [18, 19]. We constructed
activity matrices for each cancer by fusing mutation, copy-number, and expression data.
All reported P-values are nominal as they are only used for ranking.
Cancer-essentiality prioritizes known cancer genes
A byproduct of the knowledge-base design is that it allows defining hypothesis-driven
selection of study sets and calculating cancer-essentiality in the study sets. A full list of
studies in each study set is in Additional file 2. Study sets can be flexibly redefined by the
user and the knowledge-base is user-extendable with additional studies.
We used GOPredict to characterize the cancer-essentiality of genes in activating, inac-
tivating and survival-associated study sets using the K-rank. The genes, which GOPredict
characterized to be cancer-essential, include known cancer genes such as EGFR, ERBB2
and FGFR3, tumor suppressors such as RB1, TP53 and PTEN as well as genes not
previously associated with cancer (full results in Additional files 1, 3 and 4). This anal-
ysis shows that the K-rank accurately prioritizes cancer genes based on data in the
knowledge-base.
Kinase inhibitors are prioritized in primary breast tumors
In addition to cancer-essentiality, we prioritized drugs in two primary tumor data sets
with GOPredict. The drug priorization analysis contains only those drugs that have at
least one altered gene target in either BRCA or OVCA activity matrices. Out of 1559
drug-gene pairs in the knowledge-base, we calculated GOPredict scores for a total of 504
drugs in BRCA and 493 drugs in OVCA. Of the drugs 269 overlapped between the two
cancer types.
As a proof-of-concept, we first analyzed a query data set containing all BRCA sam-
ples with a immunohistochemically verified ERBB2 amplification according to TCGA
clinical data. In breast cancer, ERBB2 amplification is an established indicator to use
ERBB2 inhibitors with notable success [39]. As expected, drugs targeting ERBB2 domi-
nated the results with four ERBB2 inhibitors among the 10 best scoring drugs (Additional
file 4). This analysis shows that GOPredict accurately prioritizes subtype-specific drug
targets when such exist. Thus, for a novel cancer subtype defined with molecular features,
GOPredict could immediately suggest efficient interventions.
To test the sensitivity of GOPredict to the choice of study sets, we added three TCGA
methylation studies and re-analyzed the ERBB2 amplified query data set. In addition, we
performed a second re-analysis on the same data where instead of adding we removed
two studies. Results from both re-analyses were highly concordant with the original anal-
ysis for both cancer-essentiality and drug prioritization scores (Additional file 1). This
suggests that GOPredict scoring is robust to changes in study sets.
To obtain a general view on drug sensitivity patterns in breast cancer, we analyzed the
entire BRCA cohort. Drugs targeting matrix metalloproteinases and fibroblast growth
factor receptors (FGFR) are ranked the highest in the entire sample set (Additional file 4).
FGFR inhibitors have the largest patient group for therapeutic targeting (174–211 sen-
sitive samples, 35–42 % of samples, Fig. 2). Drugs targeting the Smoothened protein
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Fig. 2 Heat map of sample stratification according to FGFR3 status in TCGA breast tumors. Breast cancer
tumors are on the x-axis. Y-axis contains gene activity matrix statuses and immunohistochemical (IHC) status
of ER, PR and HER2. PAM50 subtype classification is on the top-most row. FGFR inhibitors dovitinib, lenvatinib
and ponatinib (dov/len/pon) share sensitive samples (green). Samples have been ordered according to FGFR
inhibitor sensitivity status
(erismodegib, saridegib and vismodegib) are also among the ten highest ranking drugs
(34 samples).
Sample stratification shows luminal breast cancers as putative targets of FGFR inhibition
Sample stratification according to sensitivity to FGFR inhibitors dovitinib, lenvatinib and
ponatinib is shown in Fig. 2. The figure depicts a categorical heat map containing activ-
ity matrix statuses of target genes that were used in the sensitivity prediction (ABL1,
BCR, FTL3 and RET), all FGFR family members (FGFR1-4) and possible confounders
(BRCA1, BRCA2, TP53 and ERBB2). In addition, the immunohistochemical staining sta-
tus of estrogen receptor, progesterone receptor and HER2 receptor are shown. Samples
sensitive to the three drugs were assigned almost exclusively according to FGFR3 acti-
vation status (97 % overlap, Fig. 2). The sensitive samples for all three drugs overlapped
completely.
To further characterize the sensitive samples, we compared GOPredict’s strata to
the PAM50 subtypes. PAM50 is a gene expression based molecular subtyping method
for breast cancer and is well established [40]. FGFR inhibitor sensitive samples com-
prised samples from every PAM50 breast cancer molecular subtype but exhibited a
clear enrichment of luminal samples. Basal, HER2-enriched and normal samples showed
no differences in the proportion of sensitive samples (Fisher’s exact test P = 1). The
proportion of sensitive samples in these three subtypes differed significantly from lumi-
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nal A (Fisher’s exact test P = 0.0006) and luminal B proportions (Fisher’s exact test
P = 0.00001). In addition, FGFR3 inhibitor sensitive samples were enriched in luminal B
samples when compared directly with luminal A (Fisher’s exact test P = 0.004). In sum-
mary, luminal subtypes in general and preferentially luminal B breast cancer samples were
significantly enriched for FGFR inhibitor sensitive samples according to activity patterns
of FGFR inhibitor targets.
GOPredict prioritizes kinase inhibitors in an independent ovarian cancer cohort
In addition to breast cancer, we tested GOPredict in an independent set of ovarian ade-
nocarcinoma primary tumors. In OVCA (Additional file 4), CDK inhibitors (dinaciclib,
alsterpaullone) received substantially higher ranks (first and second) and a large num-
ber of sensitive samples (308 to 356 samples). The multi-target tyrosine kinase inhibitor
bosutinib attained the third highest score and a comparatively large number of sensitive
samples (341 samples). All in all, the top ten scoring drugs in ovarian sample set were
enriched for CDK specific inhibitors (7/10 drugs).
Discussion
In precision medicine, molecular markers are used to tailor drug treatment for patients to
maximize clinical benefit [8]. The large number of available compounds has led to a need
to match molecular profiles of a tumor to a potentially effective therapy. Accordingly,
integrative computational methods are needed to match patient strata to appropriate
drugs.
We have presented here a novel approach to facilitate precision medicine via the
use of pathway and existing public data as well as an integrative framework that fuses
multiple types of molecular data from tumors. GOPredict is based on a knowledge dis-
covery concept that allows “data to speak”. As shown by the knowledge-based Gene Set
Enrichment Analysis framework [41], statistical testing may be too restrictive and some-
times impossible to apply to multi-dimensional data sets since it is hard to establish null
and alternative hypotheses. The knowledge-base’s modular and extensible design allows
defining study sets flexibly for new research questions. Furthermore, the rank-based scor-
ing design in GOPredict enables the integration and comparison over varied types of
cancer, measurement technology and data scales.
GOPredict prioritized FGFR inhibitors as the major class of putatively effective thera-
peutics in breast cancer. Signaling via FGFR family members plays a role in tumorigenesis
and drug sensitivity in breast cancer [42] and other solid tumors [43]. Our results suggest
the involvement of FGFRs in breast and ovarian cancer and that a substantial proportion
of breast tumors are potentially sensitive to FGFR inhibition. Pan-kinase inhibitors have
varied binding affinity to their target proteins [44] but these data are not feasibly available
for automated algorithms.
Five of the top ten prioritized drugs for breast cancer were FGFR inhibitors. All five
are in Phase 2 or 3 trials for multiple cancers [45] and pazopanib as well as dovitinib
have active breast cancer trials (https://clinicaltrials.gov/, Accessed 25 Jan 2015). Many
of our predicted sensitive samples harbored genomic alterations in FGFRs. One of the
first clinical breast cancer studies where the selection of patients was based on FGFR1
amplification status, found dovitinib to reduce tumor size more in FGFR1 amplified than
non-amplified patients [46].
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The samples predicted to be FGFR inhibitor sensitive were almost exclusively FGFR3
activated and were enriched for PAM50 luminal A and B breast cancer subtypes. Luminal
breast cancers are characterized by estrogen receptor (ER) positivity [40]. Tamoxifen is
a targeted estrogen receptor inhibitor used for adjuvant endocrine treatment of estrogen
or progesterone receptor positive breast tumors [47]. Interestingly, FGFR3 expression is
higher in breast tumors that are resistant to tamoxifen [48] and high expression of FGFR4
predicts poor response to tamoxifen therapy in primary tumors [49]. Furthermore, inva-
sive lobular breast carcinoma cell lines are sensitive to a combined inhibition of ER and
FGFR activity [50]. Our results suggest that this sensitivity to combinatorial treatment is
due to activation of FGFR3.
Tamoxifen resistant breast tumors have been found to be sensitive to vismodegib
(Smoothened antagonist) in xenograft mice [51]. In our analysis vismodegib was one
of the three Smoothened inhibitors in our priority list in breast cancer. This suggests
that tamoxifen resistant breast tumors could benefit from a combinatorial therapy with
Smoothened and FGFR inhibitors.
In our breast cancer data, roughly 20 % of HER2 positive tumors had potentially acti-
vating alterations in FGFR3. According to current guidelines, HER2 positive patients are
pharmacologically treated with HER2 inhibitors [52]. Our results with GOPredict sug-
gest that HER2 inhibitor insensitive tumors could be amenable to treatment with FGFR3
inhibitors and that a fifth of patients would stand to benefit from this treatment.
Amiloride was the highest ranked drug in HER2 positive tumors. Amiloride is a
pyrazine compound used to treat hypertension and heart failure. Interestingly, amiloride
and its derivatives have been recently suggested to have anti-cancer effects in breast can-
cer cells independent of subtype [53, 54]. An earlier study, however, found amiloride
to increase cell motility in HER2 positive breast cancer cells [55]. Taken together, these
results warrant further study to determine the applicability of amiloride to breast cancer.
In ovarian cancer, seven out of ten top priority drugs are cyclin-dependent kinase
(CDK) inhibitors. CDKs are a family of protein kinases that participate in the cell cycle
and are targeted by several inhibitors [56]. Several CDKs are potential oncogenes includ-
ing CDK4 in ovarian cancer [57]. To date, several CDK inhibitors are in Phase 2 and 3
trials [58] and of the seven CDK inhibitors in our result list flavopiridol is undergoing
Phase 2 trials in ovarian cancer as a combination treatment with oxaliplatin or cisplatin
(https://clinicaltrials.gov/, Accessed 25 Jan 2015). Moreover, dinaciclib, the highest scor-
ing CDK inhibitor by GOPredict, has been shown to sensitize ovarian cancer cell lines to
platinum drugs via downregulation of BRCA1 [59, 60]. These results suggest that a sizable
fraction of ovarian tumors are potentially sensitive to CDK inhibitors when combined
with chemotherapy.
Our knowledge-base contains both in-house and curated microarray data sets from
multiple microarray platforms and sources. Since GOPredict is designed to be extendable
and to contain data sets from multiple sources, preprocessing steps such as normaliza-
tion cannot be fully standardized and can therefore induce some noise. Nonetheless, our
results with varying study sets indicate that GOPredict scoring is robust to noise in the
study data.
GOPredict is dependent on centralized and frequently maintained databases such as
GO and Ensembl. Many databases, however, undergo changes in both data content and
database interfaces. These changes increase the maintenance burden of tools such as
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GOPredict. GOPredict could be improved in the future in three ways: (1) the addition of
binding-affinity of drug-target pairs to weight each drug target gene; (2) inclusion of data
on drug combinations and synthetic lethal interactions and; (3) addition of more result
databases. Data on the first two points are currently scattered and automated retrieval is
infeasible. GOPredict utilizes many result databases but this list is incomplete. For exam-
ple, the Comparative Toxicogenomics Database (CTD) contains special disease related
GO annotations as well as breast and ovarian cancer marker gene studies which could be
incorporated into GOPredict [61].
GOPredict results can in future work guide experimental design. For example, top scor-
ing drugs from our GOPredict analysis could be administered to breast cells with suitable
genetic profiles to test their efficacy in vitro.
GOPredict produces several by-product results when prioritizing drugs. For example,
SLC25A32 received high cancer-essentiality scores through alterations in both ovarian
and breast cancer study sets which could indicate a role for SLC25A32 in these can-
cers. Accordingly, we built a multivariate Cox survival model in TCGA OVCA data
and found that the overexpression of SLC25A32 (ANOVA P = 0.003) and lack of
residual tumor (ANOVA P = 0.02) were significant independent predictors of poor
survival (Additional file 1). SLC25A32 is folate transporter localized in mitochondria
[62]. Folates are required for DNA replication in cell division and have a dual role in
cancer drug efficacy [63]. Since ovarian tumors express moderate levels of SLC25A32
[64], our results suggest that ovarian tumors might be sensitive to antifolate chemother-
apy substances such as methotrexate which is pending results from clinical trials
(https://clinicaltrials.gov/, Accessed 25 Jan 2015).
Conclusions
Here we present GOPredict, which is a novel approach to integrate information from
multiple public sources, signaling pathway and drug target data with local genomic data
in cancer. Our results suggest that GOPredict can augment current pathology-based def-
initions of patient groups for targeted drug therapies which can potentially benefit many
cancer patients. A practical application for GOPredict is to screen genomic measure-
ments of cancer model systems for previously overlooked druggable genomic alterations
and simultaneously prioritize which drugs to screen.
Our approach is able to infer kinase inhibitors as highly relevant drugs in breast and
ovarian cancer based solely on signaling pathway information, pre-existing genomic
result data and molecular measurement data. These inhibitors are prime candidates for
further testing in drug repositioning experiments. Furthermore, our results highlight
none-cancer drugs such as amiloride which have only recently been tested for anti-cancer
efficacy with promising results. Our primary results indicate that FGFR inhibitors in
breast cancer and CDK inhibitors in ovarian cancer as well as pazopanib in both cancers
are predicted to have the largest proportion of putatively sensitive samples.
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